PMID- 28523459
OWN - NLM
STAT- MEDLINE
DCOM- 20180627
LR  - 20220318
IS  - 1720-8386 (Electronic)
IS  - 0391-4097 (Linking)
VI  - 40
IP  - 11
DP  - 2017 Nov
TI  - Plasma vascular endothelial growth factor B levels are increased in patients with 
      newly diagnosed type 2 diabetes mellitus and associated with the first phase of 
      glucose-stimulated insulin secretion function of beta-cell.
PG  - 1219-1226
LID - 10.1007/s40618-017-0677-z [doi]
AB  - PURPOSE: To detect plasma vascular endothelial growth factor B (VEGF-B) in 
      individuals with different glucose tolerance and investigate the relationship 
      between plasma VEGF-B levels and the first phase of glucose-stimulated insulin 
      secretion. METHODS: A cross-sectional study was conducted involving 45 patients 
      with newly diagnosed type 2 diabetes mellitus (T2DM), 37 patients with impaired 
      glucose regulation (IGR), and 39 Normal glucose tolerance (NGT) subjects, all of 
      whom underwent intravenous glucose tolerance test. Plasma VEGF-B levels were 
      assayed by ELISA. The first phase of insulin secretion was evaluated by acute 
      insulin response (AIR), the area under the curve of the first-phase (0-10 min) 
      insulin secretion (AUC) and glucose disposition index (GDI). RESULTS: The T2DM 
      and IGR groups had higher plasma VEGF-B levels than the NGT group (P < 0.01). 
      Plasma VEGF-B levels were negatively correlated with AIR, AUC, GDI, HOMA-beta 
      (P < 0.01), and positively correlated with plasma glucose, HbA1c, triglyceride, 
      free fatty acid (FFA), fasting insulin, and HOMA-IR (P < 0.01). Logistic 
      regression analysis revealed that higher VEGF-B levels [145.59-180.07 pg/ml, OR 
      3.55 (95% CI 1.05-12.02) and >180.07 pg/ml, OR 3.64 (95% CI 1.16-11.42)] were 
      related to a greater probability of beta-cell hypofunction, compared with low VEGF-B 
      levels (<145.59 pg/ml). After adjusting for triglyceride or FFA, the association 
      between VEGF-B levels and beta-cell hypofunction disappeared (P > 0.05). 
      CONCLUSIONS: Our study provides evidence that plasma VEGF-B levels were higher in 
      patients with newly diagnosed T2DM, and were strongly associated with glucose and 
      lipid metabolism and the first-phase insulin secretion function of beta-cells. 
      VEGF-B may be involved in the mechanism of beta-cell dysfunction in T2DM.
FAU - Wu, J
AU  - Wu J
AD  - Department of Endocrinology, The First Affiliated Hospital of Chongqing Medical 
      University, No. 1 Youyi Road, Yuan Jiagang, Yuzhong District, Chongqing, 400016, 
      People's Republic of China.
FAU - Wei, H
AU  - Wei H
AD  - Department of Endocrinology, The First Affiliated Hospital of Chongqing Medical 
      University, No. 1 Youyi Road, Yuan Jiagang, Yuzhong District, Chongqing, 400016, 
      People's Republic of China.
FAU - Qu, H
AU  - Qu H
AD  - Department of Endocrinology, The First Affiliated Hospital of Chongqing Medical 
      University, No. 1 Youyi Road, Yuan Jiagang, Yuzhong District, Chongqing, 400016, 
      People's Republic of China.
FAU - Feng, Z
AU  - Feng Z
AD  - Department of Endocrinology, The First Affiliated Hospital of Chongqing Medical 
      University, No. 1 Youyi Road, Yuan Jiagang, Yuzhong District, Chongqing, 400016, 
      People's Republic of China.
FAU - Long, J
AU  - Long J
AD  - Department of Endocrinology, The First Affiliated Hospital of Chongqing Medical 
      University, No. 1 Youyi Road, Yuan Jiagang, Yuzhong District, Chongqing, 400016, 
      People's Republic of China.
FAU - Ge, Q
AU  - Ge Q
AD  - Department of Endocrinology, The First Affiliated Hospital of Chongqing Medical 
      University, No. 1 Youyi Road, Yuan Jiagang, Yuzhong District, Chongqing, 400016, 
      People's Republic of China.
FAU - Deng, H
AU  - Deng H
AUID- ORCID: 0000-0002-7912-6508
AD  - Department of Endocrinology, The First Affiliated Hospital of Chongqing Medical 
      University, No. 1 Youyi Road, Yuan Jiagang, Yuzhong District, Chongqing, 400016, 
      People's Republic of China. deng_huacong@126.com.
LA  - eng
PT  - Journal Article
DEP - 20170518
PL  - Italy
TA  - J Endocrinol Invest
JT  - Journal of endocrinological investigation
JID - 7806594
RN  - 0 (Sweetening Agents)
RN  - 0 (VEGFB protein, human)
RN  - 0 (Vascular Endothelial Growth Factor B)
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
MH  - Cross-Sectional Studies
MH  - Diabetes Mellitus, Type 2/*blood/drug therapy/*pathology
MH  - Female
MH  - Glucose/*pharmacology
MH  - Glucose Tolerance Test
MH  - Humans
MH  - Insulin-Secreting Cells/drug effects/metabolism/*pathology
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Sweetening Agents/pharmacology
MH  - Vascular Endothelial Growth Factor B/*blood
OTO - NOTNLM
OT  - Diabetes
OT  - Intravenous glucose tolerance test
OT  - Lipid metabolism
OT  - The first phase of insulin secretion
OT  - Vascular endothelial growth factor B
EDAT- 2017/05/20 06:00
MHDA- 2018/06/28 06:00
CRDT- 2017/05/20 06:00
PHST- 2016/12/28 00:00 [received]
PHST- 2017/04/21 00:00 [accepted]
PHST- 2017/05/20 06:00 [pubmed]
PHST- 2018/06/28 06:00 [medline]
PHST- 2017/05/20 06:00 [entrez]
AID - 10.1007/s40618-017-0677-z [pii]
AID - 10.1007/s40618-017-0677-z [doi]
PST - ppublish
SO  - J Endocrinol Invest. 2017 Nov;40(11):1219-1226. doi: 10.1007/s40618-017-0677-z. 
      Epub 2017 May 18.